Joffrey van Prehn
Overview
Explore the profile of Joffrey van Prehn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
499
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Groenewegen B, van Lingen E, Kovynev A, van den Berg A, Berssenbrugge E, Sanders I, et al.
Clin Microbiol Infect
. 2024 Dec;
PMID: 39662821
Objectives: The objectives of this study are to investigate the presence of Clostridioides difficile in faeces of patients with recurrent C. difficile infection (rCDI) before and after faecal microbiota transplantation...
2.
Hanssen J, Gademan M, Wouthuyzen-Bakker M, Davis J, Dewar D, Manning L, et al.
J Infect
. 2024 Oct;
89(6):106316.
PMID: 39413929
Objectives: To identify global differences in the use of suppressive antimicrobial therapy (SAT) in the management of prosthetic joint infection (PJI). Methods: An online survey was designed to investigate clinician's...
3.
Leegwater E, Baidjoe L, Wilms E, Visser L, Touw D, de Winter B, et al.
Clin Pharmacol Ther
. 2024 Aug;
117(1):184-192.
PMID: 39148353
The goal of the study was to describe the population pharmacokinetics of trimethoprim, sulfamethoxazole, and N-acetyl sulfamethoxazole in hospitalized patients. Furthermore, this study used the model to optimize dosing regimens...
4.
Hanssen J, van der Wal R, van der Linden H, van Prehn J, Scheper H, de Boer M
J Bone Jt Infect
. 2024 Jun;
9(3):149-159.
PMID: 38903857
: Limited data inform about the optimal dosing and duration of suppressive antimicrobial therapy (SAT) for orthopedic implant infection (OII). We aimed to compare the effectiveness of low-dosage with standard-dosage...
5.
Cuperus T, Wit B, Castelijn G, Hengeveld P, Opsteegh M, Van der Giessen J, et al.
One Health
. 2024 May;
18:100739.
PMID: 38707933
Background: is a leading cause of infectious diarrhea in both humans and livestock. In particular, strains belonging to sequence type (ST) 11 are common enteropathogens. The aim of this study...
6.
Fitzpatrick F, Brennan R, van Prehn J, Skally M, Brady M, Burns K, et al.
Adv Exp Med Biol
. 2024 Jan;
1435:57-84.
PMID: 38175471
Clostridioides difficile infection (CDI) remains a significant cause of morbidity and mortality worldwide. Historically, two antibiotics (metronidazole and vancomycin) and a recent third (fidaxomicin) have been used for CDI treatment;...
7.
van Prehn J, Crobach M, Baktash A, Duszenko N, Kuijper E
Adv Exp Med Biol
. 2024 Jan;
1435:33-56.
PMID: 38175470
Diagnosis of Clostridioides difficile infection (CDI) can be challenging. First of all, there has been debate on which of the two reference assays, cell cytotoxicity neutralization assay (CCNA) or toxigenic...
8.
Veloo A, Boiten K, Hendrickx A, van Prehn J, Rossen J
Clin Microbiol Infect
. 2023 Dec;
30(4):554-555.
PMID: 38141819
No abstract available.
9.
van Prehn J, Skinner A, Krutova M, Guery B
Clin Microbiol Infect
. 2023 Oct;
30(2):261-262.
PMID: 37865336
No abstract available.
10.
van Prehn J, Chernova V, Vendrik K, Kuijper E
Ned Tijdschr Geneeskd
. 2023 Oct;
167.
PMID: 37850615
Here, we describe the epidemiology, diagnostics, and treatment of infection (CDI) in the primary health care setting. CDI is traditionally considered as a healthcare associated infection. However, infections with onset...